Due to the upstream role of epigenetic alterations in breast cancer phenotypes, we attempted to establish a method for tumor burden assessment by monitoring the DNMT1 activity levels in plasma samples from patients with different stages of breast cancer. The gene discussed is DNMT1; the disease is breast carcinoma.